Threshold Pharmaceuticals, Inc (THLD): Opiniones

Ok gracias Enola. Vamos siguiéndola.
Has visto la marcha que lleva Aixtron ?
S2

A ver si continua la pauta de recuperación y alcanza los 21 USD durante el año,

Suerte,

Gracias. Como es alemana sigo en bolsa Frankfurt y hoy ha subido más del 7 por cien. Esperaba información para entrar en ella.
S2

Para Enola y Solrac
Al final entré en Aixtron a 13,25 en una frenada de la subida. Agradeceré más información sobre ella.
Saludos a los dos

Al final, ayer presento resultados del tto. para el cáncer de páncreas?
NO he vista nada por ahí.

No,
Hay que esperar 1-2 semanas,

Cuando tenga cualquier actualización o noticia la subo sin falta

Lo bueno es que las opciones ya está cotizando precios > 4.40 (la de marzo) eso es buena señal ya que están dando una probabilidad > 50% de que los resultados sean del agrado de la comunidad científica.

Puede repuntar a 6-7-8 dependiendo de la calidad de los mismos.

Felicidades,

*
-
Ahora tiene
1.Congreso de Hipoxia en NY
2.Resultados post Merck Agreement
3.Fase III de Tejidos de Sarcomas Blandos, dónde es mejor que Zeltia por ejemplo (para Mayo-Junio 2012)

Recibe 35 millones adicionales por hito

-
No normal sería que tuviera una capitalizaciónd e 280-300 millones de $ , es decir unos 6 $.
-
El próximo año puede valer 1.200-1.400 kilos - Es la nueva Dendreon

Threshold Pharmaceuticals Announces Positive Phase 2b Clinical Trial Results of TH-302 in Patients With Pancreatic Cancer
SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- 02/21/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD)

Primary endpoint of Progression Free Survival was met with hazard ratio of 0.61 (p = 0.005).
The combination therapy was well tolerated with a safety profile consistent with prior studies.
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that its 214 patient randomized controlled Phase 2b clinical trial evaluating the efficacy and safety of two doses of the investigational agent TH-302 in combination with gemcitabine compared to gemcitabine alone in patients with first-line advanced pancreatic cancer achieved its primary endpoint, with a 63% improvement in progression free survival and a safety profile consistent with previous studies. "With the results of this trial, we are again very encouraged that TH-302 is conferring benefit to patients with aggressive and difficult to treat cancers," said Barry Selick, Ph.D., Chief Executive Officer of Threshold. "We look forward to its ongoing development with our partner Merck KGaA in this and other indications."

Clinical Trial Design
Study TH-CR-404 is a multi-center, randomized, controlled, dose-ranging, Phase 2b crossover clinical trial of TH-302 in combination with gemcitabine in patients with first line advanced pancreatic cancer. The primary endpoint of the trial is progression-free survival. The secondary endpoints are overall response rate, overall survival, change in CA19-9 as well as various other efficacy and safety parameters. Tumor response was evaluated at baseline and every eight weeks using RECIST. Patients for whom monotherapy with gemcitabine is considered standard therapy were eligible for the trial. Patients were randomized equally into one of three cohorts: TH-302 at a dose of 240 mg/m2 plus gemcitabine, TH-302 at a dose of 340 mg/m2 plus gemcitabine, or gemcitabine alone. Patients who successfully completed six cycles of treatment without evidence of significant treatment-related toxicity or progressive disease could continue to receive treatment. If a patient experienced cancer progression on gemcitabine alone, the patient could cross over into one of the TH-302 plus gemcitabine cohorts. The primary efficacy analysis was performed based upon 149 investigator-assessed PFS events and, per protocol, pooled data from the two gemcitabine plus TH-302 dose groups in comparison to gemcitabine alone.

Results
The median progression-free survival (PFS) was 5.6 months for patients treated with gemcitabine in combination with TH-302 at 240 mg/m2 and 340 mg/m2 compared to 3.6 months for patients treated with gemcitabine alone. The PFS hazard ratio comparing the TH-302 combination to gemcitabine alone was 0.61 (95% confidence interval: 0.43 - 0.87) which was highly statistically significant (p = 0.005). The response rate in the combination arms was 22% compared to 12% in the gemcitabine alone group. Results also demonstrated greater efficacy in the higher TH-302 dose group compared to the lower dose group.

The combination was well tolerated with a safety profile that was consistent with our prior study of this combination regimen. As in that study, skin and mucosal toxicities related to TH-302 were dose dependent but not dose limiting. Further detailed information regarding the results of this trial will be presented at a future major medical conference.

"This study provides the proof of concept demonstration that TH-302 contributes to the efficacy of a known active agent and supports the rationale for combining TH-302, a hypoxia targeting agent, with other approved therapies," said Stew Kroll, Senior Vice President of Biostatistics and Clinical Operations of Threshold.

About Pancreatic Cancer
Pancreatic cancer is a malignant neoplasm of the pancreas with current treatment options including surgery, radiotherapy and chemotherapy. Gemcitabine as a single agent or in combination with other treatments is the most commonly used chemotherapeutic agent in patients with advanced pancreatic cancer. It is estimated that approximately 279,000 cases of pancreatic cancer were diagnosed worldwide in 2008. Pancreatic cancer is the fourth most common cause of cancer death both in the United States and internationally. The American Cancer Society estimates that 44,030 people were diagnosed with pancreatic cancer in the United States in 2011, and approximately 37,660 people died from the disease.

El que quiera vender en la apertura está en su derecho, enhorabuena por las plusvalías.